Health and Healthcare
The First Ebola Vaccine Has Been Approved in the US
Published:
Last Updated:
NewLink Genetics Corp. (NASDAQ: NLNK) and Merck & Co. Inc. (NYSE: MRK) shares made handy gains on Friday after it was announced that the U.S. Food and Drug Administration (FDA) has granted approval to Ervebo, the Zaire Ebola virus vaccine V920.
The approval comes almost three months prior to the Prescription Drug User Fee Act (PDUFA) target FDA action date, originally set for March 14, 2020.
Overall, this represents the first vaccine approved by the FDA for the Ebola virus and follows the November 11 grant by the European Commission of a marketing authorization for Ervebo across 31 European countries.
As NewLink has previously stated, the FDA’s approval of this Ebola vaccine will trigger the issuance of a priority review voucher (PRV) owned by Merck and in which NewLink Genetics has a substantial economic interest. NewLink will have the right to monetize its share of interest in the voucher.
Eugene Kennedy, M.D., chief medical officer and member of NewLink Genetics’ Office of the CEO, commented:
We are delighted by the FDA’s decision to approve this Ebola vaccine and by the agency’s recognition of the potential this vaccine may offer to protect individuals who may be exposed to Ebola from contracting this deadly disease. We are grateful to our partner Merck, and to the regulatory bodies involved, for their dedication to advancing solutions to combat this deadly illness.
Shares of Merck were last seen up about 1.6%, at $91.46 in a 52-week range of $70.89 to $92.63. The consensus price target is $97.94.
NewLink Genetics shares were up about 14% to $1.83. The 52-week range is $1.13 to $2.27, and the consensus price target is $4.00.
24/7 Wall St.Take Charge of Your Retirement: Find the Right Financial Advisor For You in Minutes (Sponsor)
Retirement planning doesn’t have to feel overwhelming. The key is finding professional guidance—and we’ve made it easier than ever for you to connect with the right financial advisor for your unique needs.
Here’s how it works:
1️ Answer a Few Simple Questions
Tell us a bit about your goals and preferences—it only takes a few minutes!
2️ Get Your Top Advisor Matches
This tool matches you with qualified advisors who specialize in helping people like you achieve financial success.
3️ Choose Your Best Fit
Review their profiles, schedule an introductory meeting, and select the advisor who feels right for you.
Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.